Endocrinol Metab.  2015 Dec;30(4):443-455. 10.3803/EnM.2015.30.4.443.

Diagnosis and Treatment of Hypopituitarism

• Kim SY

• KMID: 2169651
• DOI: http://doi.org/10.3803/EnM.2015.30.4.443

Abstract

Hypopituitarism is a chronic endocrine illness that caused by varied etiologies. Clinical manifestations of hypopituitarism are variable, often insidious in onset and dependent on the degree and severity of hormone deficiency. However, it is associated with increased mortality and morbidity. Therefore, early diagnosis and prompt treatment is necessary. Hypopituitarism can be easily diagnosed by measuring basal pituitary and target hormone levels except growth hormone (GH) and adrenocorticotropic hormone (ACTH) deficiency. Dynamic stimulation tests are indicated in equivocal basal hormone levels and GH/ACTH deficiency. Knowledge of the use and limitations of these stimulation tests is mandatory for proper interpretation. It is necessary for physicians to inform their patients that they may require lifetime treatment. Hormone replacement therapy should be individualized according to the specific needs of each patient, taking into account possible interactions. Long-term endocrinological follow-up of hypopituitary patients is important to monitor hormonal replacement regimes and avoid under- or overtreatment.

Keyword

Hypopituitarism; Adrenocorticotropic hormone deficiency; Thyrotropin deficiency; Gonadotropin deficiency; Growth hormone deficiency; Anti-diuretic hormone deficiency

MeSH Terms

Adrenocorticotropic Hormone
Diagnosis*
Early Diagnosis
Follow-Up Studies
Growth Hormone
Hormone Replacement Therapy
Humans
Hypopituitarism*
Mortality
Adrenocorticotropic Hormone
Growth Hormone

Reference

1. Melmed S. The pituitary. 3rd ed. London: Academic press;2011.

2. Ascoli P, Cavagnini F. Hypopituitarism. Pituitary. 2006; 9:335–342.

3. Smith JC. Hormone replacement therapy in hypopituitarism. Expert Opin Pharmacother. 2004; 5:1023–1031.

4. van Aken MO, Lamberts SW. Diagnosis and treatment of hypopituitarism: an update. Pituitary. 2005; 8:183–191.

5. Prabhakar VK, Shalet SM. Aetiology, diagnosis, and management of hypopituitarism in adult life. Postgrad Med J. 2006; 82:259–266.

6. Vance ML. Hypopituitarism. N Engl J Med. 1994; 330:1651–1662.

7. Littley MD, Shalet SM, Beardwell CG, Ahmed SR, Applegate G, Sutton ML. Hypopituitarism following external radiotherapy for pituitary tumours in adults. Q J Med. 1989; 70:145–160.

8. Bhasin S, Singh AB, Javanbakht M. Neuroendocrine abnormalities associated with HIV infection. Endocrinol Metab Clin North Am. 2001; 30:749–764. viii

9. Popovic V, Aimaretti G, Casanueva FF, Ghigo E. Hypopituitarism following traumatic brain injury (TBI): call for attention. J Endocrinol Invest. 2005; 28:5 Suppl. 61–64.

10. Layman LC. Clinical genetic testing for Kallmann syndrome. J Clin Endocrinol Metab. 2013; 98:1860–1862.

11. Turkkahraman D, Saglar E, Karaduman T, Mergen H. AVP-NPII gene mutations and clinical characteristics of the patients with autosomal dominant familial central diabetes insipidus. Pituitary. 2015; 18:898–904.

12. Toogood AA, Beardwell CG, Shalet SM. The severity of growth hormone deficiency in adults with pituitary disease is related to the degree of hypopituitarism. Clin Endocrinol (Oxf). 1994; 41:511–516.

13. Reimondo G, Bovio S, Allasino B, Terzolo M, Angeli A. Secondary hypoadrenalism. Pituitary. 2008; 11:147–154.

14. Alexopoulou O, Beguin C, De Nayer P, Maiter D. Clinical and hormonal characteristics of central hypothyroidism at diagnosis and during follow-up in adult patients. Eur J Endocrinol. 2004; 150:1–8.

15. Balen AH, Manning PJ. A case of isolated TSH deficiency presenting as infertility. Postgrad Med J. 1994; 70:225–227.

16. Shalet SM, Toogood A, Rahim A, Brennan BM. The diagnosis of growth hormone deficiency in children and adults. Endocr Rev. 1998; 19:203–223.

17. Park HK. Clinical investigation of hypopituitarism: implication of combined pituitary stimulation test. J Korean Soc Endocrinol. 1996; 11:268–276.

18. Arlt W, Allolio B. Adrenal insufficiency. Lancet. 2003; 361:1881–1893.

19. Dorin RI, Qiao Z, Qualls CR, Urban FK 3rd. Estimation of maximal cortisol secretion rate in healthy humans. J Clin Endocrinol Metab. 2012; 97:1285–1293.

20. Cho HY, Kim JH, Kim SW, Shin CS, Park KS, Kim SW, et al. Different cut-off values of the insulin tolerance test, the high-dose short Synacthen test (250 µg) and the low-dose short Synacthen test (1 µg) in assessing central adrenal insufficiency. Clin Endocrinol (Oxf). 2014; 81:77–84.

21. Allahabadia A, Weetman AP. Dynamic thyroid stimulating hormone tests: do they still have a role? J Endocrinol Invest. 2003; 26:7 Suppl. 31–38.

22. Colao A, Vitale G, Cappabianca P, Briganti F, Ciccarelli A, De Rosa M, et al. Outcome of cabergoline treatment in men with prolactinoma: effects of a 24-month treatment on prolactin levels, tumor mass, recovery of pituitary function, and semen analysis. J Clin Endocrinol Metab. 2004; 89:1704–1711.

23. Johannsson G, Burman P, Wiren L, Engstrom BE, Nilsson AG, Ottosson M, et al. Low dose dehydroepiandrosterone affects behavior in hypopituitary androgen-deficient women: a placebo-controlled trial. J Clin Endocrinol Metab. 2002; 87:2046–2052.

24. Bhasin S, Cunningham GR, Hayes FJ, Matsumoto AM, Snyder PJ, Swerdloff RS, et al. Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2010; 95:2536–2559.